Reed Elsevier PLC
21 February 2005
ISSUED ON BEHALF OF REED ELSEVIER PLC AND REED ELSEVIER NV
Director's interests
We are writing to advise you that we received notifications today that the
following options were granted to directors of Reed Elsevier PLC and Reed
Elsevier NV on 17 February 2005, under the Reed Elsevier Group plc Share Option
Scheme.
Director No. of Reed Elsevier PLC options No. of Reed Elsevier NV options Exercisable
granted at 533.5p per share granted at €11.31 per share
G J A van de Aast 120,900 82,478 2008-2015
M H Armour 150,422 102,618 2008-2015
Sir Crispin Davis 292,409 199,481 2008-2015
E Engstrom 154,517 105,412 2008-2015
A Prozes 154,517 105,412 2008-2015
P Tierney 154,517 105,412 2008-2015
Exercise of the above options is subject to a post grant performance condition,
requiring the achievement of 6% per annum compound growth in adjusted EPS at
constant currencies, during the three years following the grant. There is no
re-testing of the three year EPS performance period.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.